128 related articles for article (PubMed ID: 32579977)
21. Pharmacological and behavioral profile of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-6-chinolincarboxamide (EVP-5141), a novel α7 nicotinic acetylcholine receptor agonist/serotonin 5-HT3 receptor antagonist.
Boess FG; de Vry J; Erb C; Flessner T; Hendrix M; Luithle J; Methfessel C; Schnizler K; van der Staay FJ; van Kampen M; Wiese WB; König G
Psychopharmacology (Berl); 2013 May; 227(1):1-17. PubMed ID: 23241647
[TBL] [Abstract][Full Text] [Related]
22. SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia.
Pichat P; Bergis OE; Terranova JP; Urani A; Duarte C; Santucci V; Gueudet C; Voltz C; Steinberg R; Stemmelin J; Oury-Donat F; Avenet P; Griebel G; Scatton B
Neuropsychopharmacology; 2007 Jan; 32(1):17-34. PubMed ID: 16936709
[TBL] [Abstract][Full Text] [Related]
23. Effects of BMS-902483, an α7 nicotinic acetylcholine receptor partial agonist, on cognition and sensory gating in relation to receptor occupancy in rodents.
Pieschl RL; Miller R; Jones KM; Post-Munson DJ; Chen P; Newberry K; Benitex Y; Molski T; Morgan D; McDonald IM; Macor JE; Olson RE; Asaka Y; Digavalli S; Easton A; Herrington J; Westphal RS; Lodge NJ; Zaczek R; Bristow LJ; Li YW
Eur J Pharmacol; 2017 Jul; 807():1-11. PubMed ID: 28438647
[TBL] [Abstract][Full Text] [Related]
24. Ketamine disrupted storage but not retrieval of information in male rats and apomorphine counteracted its impairing effect.
Pitsikas N; Carli M
Neurosci Lett; 2020 Oct; 737():135321. PubMed ID: 32846219
[TBL] [Abstract][Full Text] [Related]
25. A reversible model of the cognitive impairment associated with schizophrenia in monkeys: potential therapeutic effects of two nicotinic acetylcholine receptor agonists.
Buccafusco JJ; Terry AV
Biochem Pharmacol; 2009 Oct; 78(7):852-62. PubMed ID: 19577545
[TBL] [Abstract][Full Text] [Related]
26. The novel dehydroepiandrosterone (DHEA) derivative BNN27 counteracts behavioural deficits induced by the NMDA receptor antagonist ketamine in rats.
Zoupa E; Gravanis A; Pitsikas N
Neuropharmacology; 2019 Jun; 151():74-83. PubMed ID: 30959020
[TBL] [Abstract][Full Text] [Related]
27. Positive allosteric modulators of alpha 7 nicotinic acetylcholine receptors reverse ketamine-induced schizophrenia-like deficits in rats.
Nikiforuk A; Kos T; Hołuj M; Potasiewicz A; Popik P
Neuropharmacology; 2016 Feb; 101():389-400. PubMed ID: 26232639
[TBL] [Abstract][Full Text] [Related]
28. Effects of the nitric oxide synthase inhibitor L-NAME on recognition and spatial memory deficits produced by different NMDA receptor antagonists in the rat.
Boultadakis A; Pitsikas N
Neuropsychopharmacology; 2010 Nov; 35(12):2357-66. PubMed ID: 20664579
[TBL] [Abstract][Full Text] [Related]
29. Ligands selective for alpha4beta2 but not alpha3beta4 or alpha7 nicotinic receptors generalise to the nicotine discriminative stimulus in the rat.
Smith JW; Mogg A; Tafi E; Peacey E; Pullar IA; Szekeres P; Tricklebank M
Psychopharmacology (Berl); 2007 Feb; 190(2):157-70. PubMed ID: 17115136
[TBL] [Abstract][Full Text] [Related]
30. Effects of the inducible nitric oxide synthase inhibitor aminoguanidine in two different rat models of schizophrenia.
Lafioniatis A; Orfanidou MA; Papadopoulou ES; Pitsikas N
Behav Brain Res; 2016 Aug; 309():14-21. PubMed ID: 27132765
[TBL] [Abstract][Full Text] [Related]
31. In vivo pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107: preclinical considerations in Alzheimer's disease.
Bitner RS; Bunnelle WH; Decker MW; Drescher KU; Kohlhaas KL; Markosyan S; Marsh KC; Nikkel AL; Browman K; Radek R; Anderson DJ; Buccafusco J; Gopalakrishnan M
J Pharmacol Exp Ther; 2010 Sep; 334(3):875-86. PubMed ID: 20504913
[TBL] [Abstract][Full Text] [Related]
32. RG3487, a novel nicotinic α7 receptor partial agonist, improves cognition and sensorimotor gating in rodents.
Wallace TL; Callahan PM; Tehim A; Bertrand D; Tombaugh G; Wang S; Xie W; Rowe WB; Ong V; Graham E; Terry AV; Rodefer JS; Herbert B; Murray M; Porter R; Santarelli L; Lowe DA
J Pharmacol Exp Ther; 2011 Jan; 336(1):242-53. PubMed ID: 20959364
[TBL] [Abstract][Full Text] [Related]
33. Selectivity of ABT-089 for alpha4beta2* and alpha6beta2* nicotinic acetylcholine receptors in brain.
Marks MJ; Wageman CR; Grady SR; Gopalakrishnan M; Briggs CA
Biochem Pharmacol; 2009 Oct; 78(7):795-802. PubMed ID: 19481067
[TBL] [Abstract][Full Text] [Related]
34. In vitro pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107.
Malysz J; Anderson DJ; Grønlien JH; Ji J; Bunnelle WH; Håkerud M; Thorin-Hagene K; Ween H; Helfrich R; Hu M; Gubbins E; Gopalakrishnan S; Puttfarcken PS; Briggs CA; Li J; Meyer MD; Dyhring T; Ahring PK; Nielsen EØ; Peters D; Timmermann DB; Gopalakrishnan M
J Pharmacol Exp Ther; 2010 Sep; 334(3):863-74. PubMed ID: 20504915
[TBL] [Abstract][Full Text] [Related]
35. TC-5619: an alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia.
Hauser TA; Kucinski A; Jordan KG; Gatto GJ; Wersinger SR; Hesse RA; Stachowiak EK; Stachowiak MK; Papke RL; Lippiello PM; Bencherif M
Biochem Pharmacol; 2009 Oct; 78(7):803-12. PubMed ID: 19482012
[TBL] [Abstract][Full Text] [Related]
36. Ventral hippocampal alpha7 and alpha4beta2 nicotinic receptor blockade and clozapine effects on memory in female rats.
Pocivavsek A; Icenogle L; Levin ED
Psychopharmacology (Berl); 2006 Nov; 188(4):597-604. PubMed ID: 16715255
[TBL] [Abstract][Full Text] [Related]
37. Nicotinic α7 and α4β2 agonists enhance the formation and retrieval of recognition memory: Potential mechanisms for cognitive performance enhancement in neurological and psychiatric disorders.
McLean SL; Grayson B; Marsh S; Zarroug SH; Harte MK; Neill JC
Behav Brain Res; 2016 Apr; 302():73-80. PubMed ID: 26327238
[TBL] [Abstract][Full Text] [Related]
38. Differential effects of subtype-specific nicotinic acetylcholine receptor agonists on early and late hippocampal LTP.
Kroker KS; Rast G; Rosenbrock H
Eur J Pharmacol; 2011 Dec; 671(1-3):26-32. PubMed ID: 21968142
[TBL] [Abstract][Full Text] [Related]
39. Differential regulation of receptor activation and agonist selectivity by highly conserved tryptophans in the nicotinic acetylcholine receptor binding site.
Williams DK; Stokes C; Horenstein NA; Papke RL
J Pharmacol Exp Ther; 2009 Jul; 330(1):40-53. PubMed ID: 19339660
[TBL] [Abstract][Full Text] [Related]
40. Effects of the novel α7 nicotinic acetylcholine receptor agonist ABT-107 on sensory gating in DBA/2 mice: pharmacodynamic characterization.
Radek RJ; Robb HM; Stevens KE; Gopalakrishnan M; Bitner RS
J Pharmacol Exp Ther; 2012 Dec; 343(3):736-45. PubMed ID: 22988063
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
